[go: up one dir, main page]

PE20081784A1 - Metodo de tratamiento de canceres - Google Patents

Metodo de tratamiento de canceres

Info

Publication number
PE20081784A1
PE20081784A1 PE2008000322A PE2008000322A PE20081784A1 PE 20081784 A1 PE20081784 A1 PE 20081784A1 PE 2008000322 A PE2008000322 A PE 2008000322A PE 2008000322 A PE2008000322 A PE 2008000322A PE 20081784 A1 PE20081784 A1 PE 20081784A1
Authority
PE
Peru
Prior art keywords
ilideno
oxo
carboxyl
acid
treatment method
Prior art date
Application number
PE2008000322A
Other languages
English (en)
Inventor
Connie L Erickson-Miller
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690807&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081784(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20081784A1 publication Critical patent/PE20081784A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R, R1, R2 Y R3 SON CADA UNOH, ALQUILO C1-C6, FORMILO, NITRO, CIANO, HALOGENO, ENTRE OTROS; AR ES UN ANILLO AROMATICO, CICLOCO O POLICICLICO, QUE CONTIENE 3-16 ATOMOS DE CARBONO Y QUE CONTIENE ADICIONALMENTE UNO OMAS HETEROATOMOS, ENTRE OTROS; m ES 0-6. SON COMPUESTOS PREFERIDOS: ACIDO 3'-{N'-[1-(3,4-DIMETILFENIL)-3-METIL-5-OXO-1,5-DIHIDROPIRAZOL-4-ILIDENO]HIDRAZINO}-2'-HIDROXIBIFENIL-3-CARBOXILICO; ACIDO 2'-HIDROXI-3'-{N'-[2-OXO-1-(4-PROPIL-FENIL)-1,2-DIHIDRO-INDOL-3-ILIDENO]-HIDRAZIBO}-BIFENIL-4-CARBOXILICO; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGONISTAS NO PEPTIDICOS DEL RECEPTOR DE TROMBOPOYETINA (TPO) UTILES EN EL TRATAMIENTO DE SINDROMES PRECANCEROSOS
PE2008000322A 2007-02-16 2008-02-14 Metodo de tratamiento de canceres PE20081784A1 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US89023607P 2007-02-16 2007-02-16
US89255207P 2007-03-02 2007-03-02
US90820507P 2007-03-27 2007-03-27
US94934707P 2007-07-12 2007-07-12
US95228907P 2007-07-27 2007-07-27
US96919207P 2007-08-31 2007-08-31
US97721607P 2007-10-03 2007-10-03

Publications (1)

Publication Number Publication Date
PE20081784A1 true PE20081784A1 (es) 2009-01-25

Family

ID=39690807

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000322A PE20081784A1 (es) 2007-02-16 2008-02-14 Metodo de tratamiento de canceres

Country Status (28)

Country Link
US (2) US20100075928A1 (es)
EP (1) EP2124547B3 (es)
JP (1) JP5511391B2 (es)
KR (1) KR101447763B1 (es)
CN (1) CN101662937B (es)
AR (1) AR065348A1 (es)
AU (1) AU2008216106C1 (es)
BR (1) BRPI0807940B8 (es)
CA (1) CA2678358C (es)
CR (1) CR10997A (es)
DK (1) DK2124547T6 (es)
EA (1) EA017715B1 (es)
ES (1) ES2675070T7 (es)
FI (1) FI2124547T4 (es)
HU (1) HUE038563T2 (es)
IL (2) IL200319A (es)
MA (1) MA31202B1 (es)
MX (1) MX2009008822A (es)
NZ (1) NZ579068A (es)
PE (1) PE20081784A1 (es)
PL (1) PL2124547T5 (es)
PT (1) PT2124547T (es)
SI (1) SI2124547T2 (es)
TR (1) TR201809010T4 (es)
TW (1) TW200906393A (es)
UY (1) UY30915A1 (es)
WO (1) WO2008101141A2 (es)
ZA (1) ZA200905532B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
JP5393691B2 (ja) * 2007-10-09 2014-01-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 急性ヒト骨髄性白血病細胞を死滅させるトロンボポエチン受容体作用薬（ＴｐｏＲＡ）
PL3127427T3 (pl) 2009-05-29 2020-06-15 Novartis Ag Sposoby podawania związków agonistów trombopoetyny
RU2013114246A (ru) * 2010-09-01 2014-10-20 Новартис Аг Комбинация hdac ингибиторов с лекарственными средствами против тромбоцитопении
US9962370B2 (en) 2013-03-15 2018-05-08 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
RU2022100624A (ru) * 2016-05-06 2022-02-09 ТЭРИС БАЙОМЕДИКАЛ ЭлЭлСи Способ лечения рака уротелия нижних путей
RU2675695C1 (ru) * 2018-03-06 2018-12-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Способ лечения рака предстательной железы высокого и очень высокого риска

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
KR20020069183A (ko) * 1999-07-26 2002-08-29 시오노기세이야쿠가부시키가이샤 트롬보포이에틴 작동성을 나타내는 의약 조성물
ES2160560T1 (es) 1999-11-10 2001-11-16 Curacyte Ag Colorantes o,o'-dihidroxi-azoicos como constituyentes de medicamentos para el tratamiento de trombopenias.
DE60043156D1 (de) * 1999-11-10 2009-11-26 Biopheresis Technologies Inc Verfahren und system zur entfernung von zytokininhibitoren in patienten
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
TWI282785B (en) * 2000-05-30 2007-06-21 Chugai Pharmaceutical Co Ltd A compound having thrombopoietin-like activities
JP2004503217A (ja) * 2000-05-31 2004-02-05 ジェンザイム・コーポレーション 卵巣癌のための治療化合物
EP1353693B1 (en) * 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
JP4145655B2 (ja) 2001-01-26 2008-09-03 塩野義製薬株式会社 トロンボポエチン受容体アゴニスト作用を有するハロゲン化合物
WO2002059099A1 (en) 2001-01-26 2002-08-01 Shionogi & Co., Ltd. Cyclic compounds having thrombopoietin receptor agonism
WO2002062775A1 (en) 2001-02-02 2002-08-15 Yamanouchi Pharmaceutical Co., Ltd. 2-acylaminothiazole derivative or its salt
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
MXPA04002707A (es) * 2001-09-24 2005-06-06 Tosk Inc Formulaciones de cisplatina con toxicidad reducida y metodos para utilizar las mismas.
EP2314586B1 (en) 2002-01-18 2016-09-14 Astellas Pharma Inc. 2-Acylaminothiazole derivative or salt thereof
MY142390A (en) 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
AU2003268687A1 (en) 2002-09-30 2004-04-19 Yamanouchi Pharmaceutical Co., Ltd. Novel salt of 2-acylaminothiazole derivative
US20070105824A1 (en) * 2003-04-29 2007-05-10 Erickson-Miller Connie L Methods for treating degenerative diseases/injuries
WO2005118551A2 (en) 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
NZ554662A (en) * 2004-10-25 2008-11-28 Ligand Pharm Inc Thrombopoietin activity modulating compounds and methods
AU2006318527A1 (en) 2005-11-23 2007-05-31 Ligand Pharmaceuticals Incorporated Thrombopoietin activity modulating compounds and methods
MX2008011666A (es) 2006-03-15 2008-10-17 Ligand Pharm Inc Sintesis de compuestos que modulan la actividad de la trombopoyetina.

Also Published As

Publication number Publication date
TW200906393A (en) 2009-02-16
KR20090113330A (ko) 2009-10-29
US20090022814A1 (en) 2009-01-22
IL238394A0 (en) 2015-06-30
CN101662937B (zh) 2014-03-12
EA200970776A1 (ru) 2010-02-26
US20100075928A1 (en) 2010-03-25
EP2124547A2 (en) 2009-12-02
DK2124547T3 (en) 2018-07-16
BRPI0807940B1 (pt) 2020-10-27
AU2008216106C1 (en) 2025-11-13
NZ579068A (en) 2012-05-25
MX2009008822A (es) 2009-08-28
ES2675070T7 (en) 2025-08-06
IL200319A (en) 2015-05-31
EA017715B1 (ru) 2013-02-28
BRPI0807940A2 (pt) 2013-07-30
EP2124547A4 (en) 2010-05-05
ES2675070T3 (es) 2018-07-06
MA31202B1 (fr) 2010-02-01
AU2008216106A1 (en) 2008-08-21
JP2010519221A (ja) 2010-06-03
CA2678358A1 (en) 2008-08-21
IL238394B (en) 2018-05-31
PL2124547T3 (pl) 2018-08-31
EP2124547B1 (en) 2018-03-28
AU2008216106B9 (en) 2013-09-05
CA2678358C (en) 2015-12-08
DK2124547T6 (da) 2025-09-01
JP5511391B2 (ja) 2014-06-04
KR101447763B1 (ko) 2014-10-07
FI2124547T4 (fi) 2025-07-29
UY30915A1 (es) 2008-09-02
PT2124547T (pt) 2018-07-04
CN101662937A (zh) 2010-03-03
HUE038563T2 (hu) 2018-10-29
EP2124547B2 (en) 2025-04-16
EP2124547B3 (en) 2025-06-18
SI2124547T1 (en) 2018-08-31
CR10997A (es) 2009-10-16
WO2008101141A3 (en) 2008-10-16
WO2008101141A2 (en) 2008-08-21
AR065348A1 (es) 2009-06-03
BRPI0807940B8 (pt) 2021-05-25
DK2124547T4 (da) 2025-08-04
ZA200905532B (en) 2010-04-28
AU2008216106B2 (en) 2013-07-11
TR201809010T4 (tr) 2018-07-23
SI2124547T2 (sl) 2025-07-31
PL2124547T5 (pl) 2025-08-04
IL200319A0 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
PE20081784A1 (es) Metodo de tratamiento de canceres
ZA202306748B (en) Glp-1r receptor agonist compound and use thereof
AR064736A1 (es) Agonistas de gpcr
CL2008001017A1 (es) Compuestos derivados de indol, activadores de glucoquinasa; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de diabetes u obesidad.
CR9690A (es) 3-acilaminobenzanilidas insecticidas
AR064735A1 (es) Agonistas de gpcr y composicion farmaceutica en base al compuesto
PE20120578A1 (es) Agonistas y antagonistas del receptor de s1p5, y metodos de uso de los mismos
PE20091732A1 (es) Dihidropirazolonas sustituidas y su uso
AR071323A1 (es) Derivados heterociclicos de piridazinonas activadores de glucoquinasas, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de la diabetes mellitus tipo ii.
PE20091575A1 (es) Derivados bifenilo como inhibidores del virus de la hepatitis c
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
AR068813A1 (es) Derivados de pirazol sustituidos como antagonistas del receptor de androgenos (ar), un agente farmaceutico que los comprende y su uso en el tratamiento del cancer de prostata
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
ECSP109958A (es) Derivados de pirimidina 934
PE20071031A1 (es) Derivados de tiadiazolidinona como inhibidores de ptpasas
PE20170247A1 (es) Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1
PE20091413A1 (es) (DIHIDRO)PIRROLO[2,1-a] ISOQUINOLINAS
AR059249A1 (es) Compuesto amina trisustituido
PE20090813A1 (es) Inhibidores de la 11b-hidroxiesteroide-deshidrogenasa
PE20091425A1 (es) Derivados de aminotiazol
EA201170522A1 (ru) Новые гетероциклические азотсодержащие соединения, их получение и их применение в качестве антибактериальных лекарственных средств
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
ECSP088965A (es) Derivados de 2-tioxantina que actúan como inhibidores de la mpo
PE20081850A1 (es) Derivados ciclizados como inhibidores de la eg-5

Legal Events

Date Code Title Description
FC Refusal